Lilly Endowment Inc, an insider at Eli Lilly and Co (LLY), sold 95,273,380 shares on September 30, 2025, at a price of $817.65 per share. The total transaction value reached $77,900.09 million. Following this sale, Lilly Endowment Inc retains 95,273,380 shares of the company.
Eli Lilly and Co operates in the pharmaceuticals industry, focusing on the discovery, development, manufacture, and sale of pharmaceutical products. The company, based in Indianapolis, Indiana, has a market capitalization of $992.3 billion and a P/E ratio of 53.89. It employs approximately 47,000 full-time staff and has a dividend yield of 57.2%.
Upcoming earnings reports indicate an estimated EPS of $7.16 and revenue of $17.1 billion for April 29, 2026, and an estimated EPS of $7.86 with revenue of $18.7 billion for August 5, 2026.
Insider transactions must be reported to the SEC, providing insight into the stock movements of company executives and board members. While this sale represents a significant transaction, it is essential for investors to consider broader patterns of insider activity rather than isolated events when evaluating potential implications for the company’s future.